News

We are excited to share the release of our latest preprint on AOPGraphExplorer , now available on bioRxiv. Adverse Outcome Pathways (AOPs) are foundational to mechanistic toxicology and regulatory science; they map how a molecular perturbation can causally lead to an adverse outcome across levels of biological organization. These frameworks help unify and communicate complex mechanistic evidence for chemical risk assessment and safety evaluation. However, AOP knowledge in exi

New Approach Methodologies (NAMs), including in vitro tests, computational models, and in silico tools, are transforming chemical safety assessment. In many cases, the   required types of data are widely agreed upon, and this is becoming increasingly clear. What is less clear and (not yet standardized) is how this evidence is collected, combined, and reported within an NGRA (Next Generation Risk Assessment) framework. Many NAM-based assessments still rely on fragmented datase

1. Introduction: Context, Motivation, and Project Framework Nephrotoxicity Challenge:  Nephrotoxicity, or kidney injury, is a frequent outcome of exposure to a wide variety of xenobiotics and can result in acute and chronic kidney damage. Traditional toxicological assessment methods, such as animal in vivo  studies, are limited by poor predictive capacity and a lack of human relevance. Advantage of hiPSC Models:  A paradigm shift towards in vitro  testing offers new opportuni

Beyond the Cage: Human iPSC Multi-Organ Models Validate Next-Generation Chemical Risk Assessment 1. Motivation and Context Need for New...

Executive Summary The case study leveraged rat in vivo  transcriptomics data  from the DrugMatrix Database to investigate mechanisms of nephrotoxicity. The primary objective was to perform biomarker discovery  by identifying differentially expressed genes (DEGs) specific to toxic compounds compared to non-toxic compounds. The study harmonized data for several nephrotoxic and non-nephrotoxic compounds based on dose and exposure duration. Analysis revealed 109 DEGs found exclus

In the evolving landscape of chemical and pharmaceutical development, traditional methods of toxicology, which are often heavily reliant on animal testing, are facing increasing scrutiny due to ethical concerns, cost, and time constraints. Enter toxicogenomics, a revolutionary field that is transforming how we assess the safety of compounds. At Edelweiss Connect, through our SaferWorldByDesign initiative, we're at the forefront of leveraging this powerful science for early, e

Edelweiss Connect Inc.  is expanding to the United States with our new office space at the Portland State Business Accelerator (PSBA) ....

31st - Sep 4th 2025 , Rio de Janiero. We’re excited to be participating in WC13 in Brazil ! Our Edelweiss Connect team will be involved...

Contact us now to try SmartSafety --- MoCRA Requirement 1: Safety Substantiation Companies must ensure and document that their products...

With the Modernization of Cosmetics Regulation Act of 2022  (MoCRA), the FDA has introduced sweeping new requirements for cosmetics sold...